JTEC CORPORATION
3446・Standard Market・Metal Products
Business
J-TEC Corporation is an industry-academia collaboration-type precision equipment manufacturer whose management philosophy is "to create products through one-of-a-kind technology that does not exist elsewhere in the world, and to contribute broadly to society." In its core Optical Business, the company supplies ultra-high-precision X-ray Nano-focusing Mirrors under the "OsakaMirror" brand—originating from joint development with Osaka University and RIKEN—as the world's sole manufacturer, to synchrotron radiation facilities and X-ray free-electron laser facilities both in Japan and overseas. In addition, the company operates the Life Science & Equipment Development Business, which handles automated cell culture equipment and semiconductor nano-surface processing equipment, as well as a Thermal Desorption Spectrometer (TDS) business conducted through its subsidiary Electronic Science Co., Ltd., for a total of three business segments. Its customers are mainly national research institutions, universities, and advanced industry companies. The company is listed on the Prime Market of the Tokyo Stock Exchange.
Business Model
The Optical Business operates on a fully custom-made, build-to-order model, achieving a high segment profit margin of 42.7% in FY2025 (ending June 2025). Customers are centered on public research institutions worldwide (81.8% of sales), and the company's monopolistic position, with no competitors, underpins its pricing power. The Life Science & Equipment Development Business sells equipment on a fabless production basis, while Electronic Science combines TDS equipment sales with the recurring-revenue business of maintenance and contract analysis. The company as a whole continues to invest ¥282,569 thousand annually in R&D, maintaining a structure designed to preserve its technological edge.
Company Strengths
In 2005, Osaka University and RIKEN jointly developed an X-ray nano-focusing mirror capable of focusing hard X-rays to the theoretical limit, which the company commercialized. It was trademarked as "OsakaMirror" and has been sold since 2006. The company has continuously supplied major synchrotron radiation facilities worldwide, including SPring-8, SACLA, NanoTerasu, Eu-XFEL, ESRF, and LCLS, and is recognized as the sole manufacturer with a precision level that competitors cannot reach.
In FY2025 (ended June 2025), orders received in the Optical Business totaled ¥1,903 million (up 186.9% year on year), and the order backlog reached ¥1,321 million (up 202.5% year on year), both showing significant growth. Against the backdrop of fourth-generation upgrade and new construction plans at synchrotron radiation facilities worldwide (including China's HALF, IASF, and IHEP, a new facility in South Korea, and the domestic SPring-8 upgrade), a foundation for future revenue growth has been established.
The company established a joint research division within Osaka University (July 2023) and continues numerous joint research projects with Tokyo Polytechnic University, Nagoya University, Yokohama City University, the University of Tokyo, and others. It actively utilizes competitive funding from AMED, the Ministry of Economy, Trade and Industry, and other sources; total R&D expenses for FY2025 (ended June 2025) amounted to ¥282,569 thousand. Development achievements for next-generation products, including the completed performance verification of the Deformable Mirror, have also been reported at academic conferences and in papers.
ENVALITH's Perspective
Performance Trend
Net sales over the past five fiscal years trended as follows: FY2022 ¥1,151 million → FY2023 ¥1,908 million → FY2024 ¥2,010 million → FY2025 ¥1,926 million, with FY2026 full-year forecast at ¥2,655 million (up 37.9% year on year), indicating a substantial increase in revenue. Cumulative net sales for the third quarter of the fiscal year ending June 2026 were ¥1,040 million (up 7.5% year on year), maintaining the growth trend. The Optical Business was the main driver, supported by increased shipments to domestic synchrotron radiation facilities (domestic ratio exceeding 50%) and a shift toward higher-margin products, with segment profit expanding 77.7% year on year to ¥244 million. On the other hand, the Life Science & Equipment Development Business saw its segment loss widen due to increased R&D expenses, while Other Business (Electronic Science) recorded a substantially larger segment loss due to sluggish sales of TDS equipment and rising raw material prices. As for the external environment, US-China trade friction and geopolitical risks are heightening uncertainty in the business environment, but geopolitical shifts such as the reshoring of SiC device production to Japan are providing a tailwind for PAP and ECMP demand.
Growth Strategy
Aiming for medium- to long-term growth by capturing 4th-generation synchrotron radiation facility demand and expanding technology into the semiconductor and life science fields
Actively pursuing orders targeting new construction and upgrade plans including China's SHINE, HEPS, HALF, IASF, and domestic SPring-8 upgrade, NanoTerasu, etc. The acquisition of the first order from Europe for the AdvancedKB Mirror has also driven full-scale market development beyond Asia. The substantial expansion of the order backlog forms the foundation for future sales.
Requests for prototype testing of PAP and ECMP as surface processing equipment for next-generation power devices such as SiC wafers, diamond substrates, and GaN are increasing. Demand expansion is expected in the market environment due to the domestic return of SiC devices amid geopolitical circumstances and Japan-US collaboration. Continuing to strengthen technological capabilities and the sales system.
In addition to strong orders and sales of CellPet®, promoting new market development with general-purpose automated cell culture equipment such as MakCell®. The global trends of work-style reform and the prohibition of animal testing serve as tailwinds in the market environment. Conducting market surveys to respond to expanding market needs for ultra-large-scale, fully automated cell culture systems.
With outsourced production now fully operational, internal resources are being reallocated to research & development and maintenance business. A development unit of the High-Precision Temperature Measurement System ESCO-TDS1200II IR BGM for the semiconductor field has been completed and is scheduled to be presented at an academic conference. Development is underway for new products such as ESCO-TDS600 IR H2 and ESCO-TDS-100 Cryo H2, aiming for sales launch within the next fiscal year.
For the Mononuclear Cell Separator, which has produced results through the use of competitive funding, a policy to accelerate practical application and commercialization has been clearly stated. The company plans to leverage the revitalization of the regenerative medicine market (expansion of time-limited approvals for regenerative medicine products by other companies) as a tailwind in the market environment.
Last updated: July 17, 2026